Biocon Q2 Results Preview: Biocon likely to bank on Viatris acquisition; sales, margin may soar considerably
Biocon Q2 Results Preview: Biocon's biologics sales are set to double, while margin can also improve considerably due to the integration of American pharma firm Viatris, as the Bengaluru-based pharma company is set to announce its July-September quarter results on Friday (November 10).
Biocon completed its acquisition of Viatris Biosimilars' business in North America in the first week of September.
So, a fair comparison of second-quarter consolidated numbers with the outcomes of the year-ago period is not possible.
Telangana Assembly election 2023: Will BRS retain its power for a third time? Check latest voting updates, date of counting, results announcement of 119 Assembly seats
ICC T20 World Cup 2024: Uganda creates history, qualifies for T20 World Cup; Namibia in; Zimbabwe exits
Assembly Elections 2023 Exit Polls: Check when and where to view result predictions for Rajasthan, Madhya Pradesh, Chhattisgarh, Telangana, Mizoram election
This special fixed deposit (FD) scheme from Central Bank gives you guaranteed return of 7.55%, know how
Gandhar Oil Refinery India makes a strong debut on D-Street, shares list at 76% premium over issue price
Zee Business research has projected figures for Biocon's Q2 earnings, which may vary from the actual numbers Biocon delivers on Friday for the second quarter of the current financial year.
Research estimates for Biocon Q2 results
The company's consolidated profit after tax (PAT) is likely to soar by 85 per cent to Rs. 152 crore in the second quarter agianst Rs 82 crore in the year-ago period.
Biocon's revenue from operations in the September quarter is also expected to skyrocket by 57 per cent to Rs 3,640 crore compared to Rs 2,320 crore in the corresponding period last fiscal.
Biocon's integration with Viatris is most likely to propel its margin in the second quarter, which can rise to 23 per cent against the 20 per cent the company recorded in Q2 FY23.
BIocon's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBIDTA) for the second quarter is estimated to soar by 79 per cent to Rs 843 crore as against Rs 471 crore in the same quarter last year.
While the company is set to announce good consolidated numbers for the September quarter, it is also expected to report strong quarter-on-quarter figures on the back of integration with Viatris.
Since Viatris' acquisition of the North American business has also increased Biocon's market share, it is most likely to reflect in the company's Q2 growth numbers.
As far as the market commentary post results is concerned, the analysts' recommendation is to keep an eye on Biocon's new launches.